Effect of general anesthesia on pulmonary function and clinical status on children with cystic fibrosis
Chetan Pandit1, Roumel Valentin, Jonathan De Lima
1Department of Respiratory medicine, The Children's hospital at Westmead, Sydney, Australia; Discipline of Pediatrics and child health, Sydney Medical School, University of Sydney, Sydney, Australia.
Insights
General anesthesia (GA) in children with cystic fibrosis (CF) appears safe, with no significant impact on lung function or clinical status. Modern anesthetic techniques show improved safety compared to historical data for pediatric CF patients.
Area of Science:
- Pediatric Anesthesiology
- Cystic Fibrosis Research
- Pulmonary Medicine
Background:
- Children with cystic fibrosis (CF) often require general anesthesia (GA) for various procedures.
- Historical data suggest a high risk of morbidity associated with GA in CF patients.
- Limited data exist on the safety of current anesthetic agents in pediatric CF populations.
Purpose of the Study:
- To assess the impact of general anesthesia (GA) on the clinical status and lung function of children with cystic fibrosis (CF).
- To evaluate the safety of modern anesthetic agents in pediatric CF patients.
Main Methods:
- Children aged 8-18 years with CF and pulmonary exacerbation were enrolled.
- Spirometry, forced oscillation technique (FOT), and CF clinical score (CFCS) were measured before and at 24/48 hours after GA.
- Details of anesthetic agents and duration were recorded.
Main Results:
- 19 pediatric CF patients underwent GA, primarily using propofol or sevoflurane.
- No statistically significant changes were observed in spirometry or CFCS post-GA.
- Forced oscillation technique (FOT) showed decreased resistance and reactance at 24 and 48 hours post-GA.
- Only two adverse events were reported in the cohort.
Conclusions:
- General anesthesia (GA) does not appear to cause significant deterioration in airway function for children with mild to moderate CF lung disease.
- Modern anesthesia techniques demonstrate an improved safety profile for pediatric CF patients compared to historical data.
- The low complication rate supports the safe use of current anesthetic agents in this population.
Introduction:
Children with cystic fibrosis (CF) receive general anesthesia (GA) for a variety of different procedures. Historical studies assessing risk of GA report a high risk of morbidity. There is a paucity of data evaluating the risk of currently available anesthetic agents. The aim of this study was to assess the effect of GA on clinical status and lung function on children with CF.
Methods:
Children with CF aged 8-18 years admitted for IV antibiotic treatment for a pulmonary exacerbation were invited to participate. Spirometry, forced oscillation technique (FOT), and CF clinical score (CFCS) were measured pre-GA, at 24 and 48 h post-GA. The nature and duration of the GA were recorded.
Results:
Twenty two patients were recruited of which 19 patients (mean age 11.4 years, range 8-18 years, 12 male) required GA. Typically, either propofol or sevoflurane was used as induction agent and maintenance of anesthesia was with sevoflurane. A laryngeal mask was used in most cases. FEV1 mean (±SD) pre-GA was 75.1% (±23.46) which decreased at 24 h to 74.8 (±23.0) and at 48 h to 74.3 (±20.5). FOT resistance and reactance decreased at 24 and 48 h from baseline. Changes in spirometry and CFCS were not statistically significant. Two adverse events were observed in this cohort.
Conclusion:
The results suggest that children with mild to moderate CF lung disease do not experience significant deterioration in central or peripheral airway function following GA. The low rate of complications suggests an improved level of safety for children with CF with modern anesthesia compared with historical published data.
More Related Videos
Related Concept Videos
Stages of General Anesthesia
Inhalational Anesthetics: Overview
General Anesthesia: Overview
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Atelectasis II: Pathophysiology
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History


